{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:55:06Z","timestamp":1783979706550,"version":"3.55.0"},"reference-count":78,"publisher":"Xia & He Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,28]]},"DOI":"10.14218\/jcth.2020.00034","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T23:51:02Z","timestamp":1596066662000},"page":"1-14","source":"Crossref","is-referenced-by-count":15,"title":["Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents"],"prefix":"10.14218","volume":"8","author":[{"given":"Jenny","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilu","family":"Partovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trana","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"key20200729235059_b1","unstructured":"World Health OrganizationHepatitis CAvailable from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"key20200729235059_b2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/2050640616678151","article-title":"The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions","volume":"5","author":"Smolders","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"key20200729235059_b3","doi-asserted-by":"crossref","first-page":"e0172159","DOI":"10.1371\/journal.pone.0172159","article-title":"Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study","volume":"12","author":"Kondili","year":"2017","journal-title":"PLoS One"},{"key":"key20200729235059_b4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/hiv.12570","article-title":"Management of drug interactions with direct-acting antivirals in Dutch HIV\/hepatitis C virus-coinfected patients: adequate but not perfect","volume":"19","author":"Smolders","year":"2018","journal-title":"HIV Med"},{"key":"key20200729235059_b5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/1060028015576180","article-title":"Drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients","volume":"49","author":"Burgess","year":"2015","journal-title":"Ann Pharmacother"},{"key":"key20200729235059_b6","unstructured":"Gilead SciencesEPCLUSA\u00ae (sofosbuvir\/velpatasvir) product monographAvailable from: http:\/\/www.gilead.ca\/application\/files\/9615\/6925\/4628\/Epclusa_English_PM_e186388-GS-005.pdf"},{"key":"key20200729235059_b7","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200729235059_b8","unstructured":"Gilead SciencesVOSEVI\u00ae (sofosbuvir\/velpatasvir\/voxilaprevir) product monographAvailable from: http:\/\/www.gilead.ca\/application\/files\/9615\/8258\/0557\/Vosevi_English_PM_e192340-GS-003.pdf"},{"key":"key20200729235059_b9","unstructured":"AbbVieMAVIRET\u00ae (glecaprevir\/pibrentasvir)Available from: https:\/\/www.abbvie.com\/our-science\/pipeline\/mavyret.html"},{"key":"key20200729235059_b10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.xphs.2016.10.007","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: A first-in-human study","volume":"106","author":"Lin","year":"2017","journal-title":"J Pharm Sci"},{"key":"key20200729235059_b11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.350","article-title":"Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a first-in-human study","volume":"7","author":"Lin","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key20200729235059_b12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0018578717746417","article-title":"Formulary drug reviews: Glecaprevir\/Pibrentasvir","volume":"53","author":"Levien","year":"2018","journal-title":"Hosp Pharm"},{"key":"key20200729235059_b13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciz022","article-title":"Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease","volume":"69","author":"Gane","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key20200729235059_b14","unstructured":"Merck CanadaZEPATIER\u00ae (elbasvir\/grazoprevir) product monograph2020[cited Available from: https:\/\/www.merck.ca\/confirm-monograph.xhtml?file=ZEPATIER-PM_E.pdf"},{"key":"key20200729235059_b15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"key20200729235059_b16","doi-asserted-by":"crossref","first-page":"e00813","DOI":"10.1128\/AAC.00813-17","article-title":"Effect of hepatic impairment on the pharmacokinetics of grazoprevir, a hepatitis C virus protease inhibitor","volume":"61","author":"Caro","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key20200729235059_b17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","article-title":"Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential","volume":"26","author":"Lauffenburger","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20200729235059_b18","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1016\/S0168-8278(16)01136-3","article-title":"Drug-drug interaction profile of sofosbuvir\/velpatasvir fixed-dose combination","volume":"64","author":"Mogalian","year":"2016","journal-title":"J Hepatol"},{"key":"key20200729235059_b19","article-title":"Integrated efficacy, pharmacokinetics, and safety of glecaprevir\/pibrentasvir in patients taking concomitant proton pump inhibitors and other acid-reducing drugs","volume-title":"World Congress of Gastroenterology at ACG 2017","author":"Flamm","year":"2017"},{"key":"key20200729235059_b20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cgh.2018.07.003","article-title":"Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection","volume":"17","author":"Flamm","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20200729235059_b21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/cts.12465","article-title":"No pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir\/grazoprevir and famotidine or pantoprazole","volume":"10","author":"Feng","year":"2017","journal-title":"Clin Transl Sci"},{"key":"key20200729235059_b22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/hep4.1081","article-title":"Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir\/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection","volume":"1","author":"Reau","year":"2017","journal-title":"Hepatol Commun"},{"key":"key20200729235059_b23","first-page":"673","article-title":"Sofosbuvir + amiodarone: bradycardia and conduction disturbances","volume":"35","author":"Association mieux prescrire","year":"2015","journal-title":"Rev Prescrire"},{"key":"key20200729235059_b24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1053\/j.gastro.2015.09.031","article-title":"Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned","volume":"149","author":"Back","year":"2015","journal-title":"Gastroenterology"},{"key":"key20200729235059_b25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12664-016-0684-6","article-title":"Bradyarrhythmia induced by amiodarone-sofosbuvir co-administration","volume":"35","author":"Ghembaza Mel","year":"2016","journal-title":"Indian J Gastroenterol"},{"key":"key20200729235059_b26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/toxsci\/kfw153","article-title":"Identification of drug-drug interactions in vitro: A case study evaluating the effects of sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes","volume":"154","author":"Millard","year":"2016","journal-title":"Toxicol Sci"},{"key":"key20200729235059_b27","unstructured":"PendopharmTOLOXIN\u00ae (digoxin) product monographAvailable from: https:\/\/pdf.hres.ca\/dpd_pm\/00037207.PDF"},{"key":"key20200729235059_b28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40262-015-0334-7","article-title":"Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir","volume":"55","author":"Mogalian","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"key20200729235059_b29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/jpet.119.256966","article-title":"Translation of in vitro transport inhibition studies to clinical drug-drug interactions for glecaprevir and pibrentasvir","volume":"370","author":"Kosloski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"key20200729235059_b30","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1124\/dmd.117.079038","article-title":"The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection","volume":"46","author":"Garrison","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"key20200729235059_b31","article-title":"Evaluation of transporter and cytochrome P450-mediated drug-drug interactions with the pan genotypic HCV NS3\/4A protease inhibitor voxilaprevir (GS-9857) or Sofosbuvir\/Velpatasvir\/Voxilaprevir and phenotypic probe drugs","volume-title":"17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy","author":"Kirby","year":"2016"},{"key":"key20200729235059_b32","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1016\/S0168-8278(17)31381-8","article-title":"Drug-drug interaction profile of sofosbuvir\/velpatasvir\/ voxilaprevir fixed-dose combination","volume":"66","author":"Garrison","year":"2017","journal-title":"J Hepatol"},{"key":"key20200729235059_b33","article-title":"Drug-drug interactions of glecaprevir and pibrentasvir with pravastatin, rosuvastatin, or dabigatran etexilate","volume-title":"18th International Workshop on Clinical Pharmacology of Antiviral Therapy","author":"Kosloski","year":"2017"},{"key":"key20200729235059_b34","unstructured":"Boehringer Ingelheim CanadaPradaxa\u00ae (dabigatran) product monographAvailable from: https:\/\/www.boehringer-ingelheim.ca\/sites\/ca\/files\/documents\/pradaxapmen.pdf"},{"key":"key20200729235059_b35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/tpj.2016.82","article-title":"An integrated pharmacokinetic\/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure","volume":"18","author":"Vandell","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"key20200729235059_b36","unstructured":"Servier CanadaLIXIANA\u00ae (edoxaban) product monographAvailable from: https:\/\/pdf.hres.ca\/dpd_pm\/00040392.PDF"},{"key":"key20200729235059_b37","unstructured":"European Medicines AgencyVosevi, sofosbuvir\/velpatasvir\/voxilaprevirAvailable from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vosevi"},{"key":"key20200729235059_b38","unstructured":"FDADrug development and drug interactions: table of substrates, inhibitors and inducersAvailable from: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers"},{"key":"key20200729235059_b39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clinthera.2009.02.022","article-title":"Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers","volume":"31","author":"Krishna","year":"2009","journal-title":"Clin Ther"},{"key":"key20200729235059_b40","doi-asserted-by":"crossref","first-page":"e02142","DOI":"10.1128\/AAC.02142-18","article-title":"Pharmacokinetic interactions between the hepatitis C virus inhibitors elbasvir and grazoprevir and hiv protease inhibitors ritonavir, atazanavir, lopinavir, and darunavir in healthy volunteers","volume":"63","author":"Feng","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key20200729235059_b41","unstructured":"AIDSinfoGuidelines for the use of antiretroviral agents in adults and adolescents with HIVAvailable from: https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf"},{"key":"key20200729235059_b42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200847060-00001","article-title":"A review of the pharmacokinetics of abacavir","volume":"47","author":"Yuen","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"key20200729235059_b43","unstructured":"KosloskiMPDuttaSVianiRMQiXTrinhRCampbellAGlecaprevir and pibrentasvir interactions with combination antiretroviral regimens.Conference on Retroviruses and Opportunistic Infections2017Seattle, WashingtonAvailable from: https:\/\/www.croiconference.org\/abstract\/glecaprevir-and-pibrentasvir-interactions-combination-antiretroviral-regimens\/"},{"key":"key20200729235059_b44","unstructured":"Gilead SciencesVIREAD\u00ae (tenofovir disoproxil fumarate) product monographAvailable from: http:\/\/www.gilead.ca\/application\/files\/1915\/2970\/4534\/Viread_English_PM_e131863-GS-0035.pdf"},{"key":"key20200729235059_b45","unstructured":"Gilead SciencesVEMLIDY\u00ae (tenofovir alafenamide) product monographAvailable from: http:\/\/www.gilead.ca\/application\/files\/6115\/5959\/0213\/Vemlidy_English_PM_e193066-GS-002.pdf"},{"key":"key20200729235059_b46","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/ofid\/ofw172.1696","article-title":"Lack of interaction between elbasvir\/grazoprevir and approved HIV and hepatitis B virus drugs in viral replication in vitro","volume":"3","author":"Chase","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key20200729235059_b47","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/ciy201","article-title":"Drug-drug interaction studies between hepatitis C virus antivirals sofosbuvir\/velpatasvir and boosted and unboosted human immunodeficiency virus antiretroviral regimens in healthy volunteers","volume":"67","author":"Mogalian","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key20200729235059_b48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: An open-label, phase 3 study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key20200729235059_b49","unstructured":"Gilead SciencesEmtriva\u00ae (emtricitabine) product monographAvailable from: http:\/\/www.gilead.ca\/application\/files\/9514\/9754\/8346\/emtriva_pm_english.pdf"},{"key":"key20200729235059_b50","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/COH.0000000000000377","article-title":"Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?","volume":"12","author":"Ford","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"key20200729235059_b51","unstructured":"Bristol-Myers Squibb CanadaBARACLUDE\u00ae (entecavir) product monographAvailable from: https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/BARACLUDE_EN_PM.pdf"},{"key":"key20200729235059_b52","unstructured":"KosloskiMPDuttaSDingBWangSKortJLiuWInteractions between ABT-493 plus ABT-530 combination and rilpivirine or raltegravir.Conference on Retroviruses and Opportunistic InfectionsAvailable from: https:\/\/www.croiconference.org\/abstract\/interactions-between-abt-493-plus-abt-530-combination-and-rilpivirine-or-raltegravir\/"},{"key":"key20200729235059_b53","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"key20200729235059_b54","unstructured":"Upjohn CanadaLipitor\u00ae (atorvastatin) product monographAvailable from: https:\/\/www.pfizer.ca\/sites\/default\/files\/202005\/LIPITOR_PM_E_237270_2020.04.30.pdf"},{"key":"key20200729235059_b55","article-title":"Merck Canada. MEVACOR\u00ae (lovastatin) product monograph"},{"key":"key20200729235059_b56","unstructured":"Merck CanadaZOCOR\u00ae (simvastatin) product monographAvailable from: https:\/\/www.merck.ca\/static\/pdf\/ZOCOR-PM_E.pdf"},{"key":"key20200729235059_b57","unstructured":"BegleyRMogalianEMcNabbBShenGLeeSLingJEvaluation of drug-drug interaction potential between sofosbuvir\/velpatasvir and atorvastatin.18th International Workshop on Clinical Pharmacology of Antiviral Therapy2017Chicago, ILAvailable from: http:\/\/www.natap.org\/2017\/Pharm\/Pharm_27.htm"},{"key":"key20200729235059_b58","unstructured":"Bristol-Myers Squibb CanadaPRAVACHOL\u00ae (pravastatin) product monographAvailable from: https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/PRAVACHOL_EN_PM.pdf"},{"key":"key20200729235059_b59","unstructured":"AstraZeneca CanadaCRESTOR\u00ae (rosuvastatin calcium) product monographAvailable from: https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/crestor-product-monograph-en.pdf"},{"key":"key20200729235059_b60","unstructured":"Astellas Pharma CanadaPrograf\u00ae (tacrolimus) product monographAvailable from: https:\/\/pdf.hres.ca\/dpd_pm\/00050217.PDF"},{"key":"key20200729235059_b61","unstructured":"Novartis Pharmaceuticals Canada IncNEORAL\u00ae (cyclosporine microemulsion) product monographAvailable from: https:\/\/pdf.hres.ca\/dpd_pm\/00028894.PDF"},{"key":"key20200729235059_b62","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jcph.1052","article-title":"Pharmacokinetic interactions between elbasvir\/grazoprevir and immunosuppressant drugs in healthy volunteers","volume":"58","author":"Feng","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"key20200729235059_b63","unstructured":"KosloskiMPDuttaSZhaoWPugatchDAsatryanAKortJDrug-drug interactions between next generation direct acting antivirals ABT-493 and ABT-530 with cyclosporine or tacrolimus in healthy subjects.66th Annual Meeting of the American Association for the Study of Liver DiseasesAvailable from: http:\/\/www.natap.org\/2015\/AASLD\/AASLD_27.htm"},{"key":"key20200729235059_b64","unstructured":"WyethT.M.RAPAMUNE\u00ae (sirolimus) product monographAvailable from: https:\/\/www.pfizer.ca\/sites\/default\/files\/201711\/Rapamune_PM_208129_25Oct2017_E.pdf"},{"key":"key20200729235059_b65","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200729235059_b66","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200729235059_b67","article-title":"Lack of pharmacokinetic drug-drug interaction between norgestimate\/ethinyl estradiol and sofosbuvir\/velpatasvir\/voxilaprevir","author":"Garrison","journal-title":"18th International Workshop on Clinical Pharmacology of Antiviral Therapy"},{"key":"key20200729235059_b68","unstructured":"Committee for Medicinal Products for Human Use (CHMP)Assessment report: VoseviAvailable from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vosevi-epar-public-assessment-report_en.pdf"},{"key":"key20200729235059_b69","unstructured":"Committee for Medicinal Products for Human Use (CHMP)Assessment report: MaviretAvailable from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/maviret-epar-public-assessment-report_en.pdf"},{"key":"key20200729235059_b70","unstructured":"Janssen IncMICRONOR\u00ae (norethindrone) product monographAvailable from: https:\/\/pdf.hres.ca\/dpd_pm\/00018763.PDF"},{"key":"key20200729235059_b71","unstructured":"Paladin Labs IncMETADOL. \u00ae (methadone) product monographAvailable from: https:\/\/pdf.hres.ca\/dpd_pm\/00034071.PDF"},{"key":"key20200729235059_b72","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/cts.12564","article-title":"No pharmacokinetic interactions between elbasvir or grazoprevir and methadone in participants receiving maintenance opioid agonist therapy","volume":"11","author":"Feng","year":"2018","journal-title":"Clin Transl Sci"},{"key":"key20200729235059_b73","doi-asserted-by":"crossref","first-page":"ofy001","DOI":"10.1093\/ofid\/ofy001","article-title":"Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies","volume":"5","author":"Grebely","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"key20200729235059_b74","doi-asserted-by":"crossref","first-page":"e00958","DOI":"10.1128\/AAC.00958-17","article-title":"No clinically relevant drug-drug interactions between methadone or buprenorphine-naloxone and antiviral combination glecaprevir and pibrentasvir","volume":"61","author":"Kosloski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key20200729235059_b75","unstructured":"Indivior UKSUBOXONE\u00ae (buprenorphine and naloxone) product monographAvailable from: https:\/\/pdf.hres.ca\/dpd_pm\/00041074.PDF"},{"key":"key20200729235059_b76","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/cts.12565","article-title":"No pharmacokinetic interactions between elbasvir or grazoprevir and buprenorphine\/naloxone in healthy participants and participants receiving stable opioid agonist therapy","volume":"11","author":"Feng","year":"2018","journal-title":"Clin Transl Sci"},{"key":"key20200729235059_b77","unstructured":"Sandoz Canada IncFENTANYL CITRATE INJECTION SDZ (fentanyl citrate injection) product monographAvailable from: https:\/\/pdf.hres.ca\/dpd_pm\/00042422.PDF"},{"key":"key20200729235059_b78","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1034\/j.1600-0676.2001.021004260.x","article-title":"Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C","volume":"21","author":"Herold","year":"2001","journal-title":"Liver"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2020.00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:19:16Z","timestamp":1783707556000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2020.00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,7,30]]},"published-print":{"date-parts":[[2020,9,28]]}},"alternative-id":["10.14218\/JCTH.2020.00034"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2020.00034","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,30]]}}}